Elite in Subacute Combined Degeneration

Jie Q. Cao

Union Hospital, 
Wuhan, CN 
Elite in Subacute Combined Degeneration
Union Hospital, 
Wuhan, CN 
OverviewLocationsClinical Research

Overview

Jie Cao practices in Wuhan, China. Cao is rated as an Elite expert by MediFind in the treatment of Subacute Combined Degeneration. Their top areas of expertise are Subacute Combined Degeneration, Cerebral Hypoxia, Obstructive Sleep Apnea, Thrombectomy, and Endoscopy.

Their clinical research consists of co-authoring 1316 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 4 articles in the study of Subacute Combined Degeneration.

Locations

Union Hospital, Wuhan, 430022, China
Other Locations
Xinmin Street 1#, Changchun, China
160 Pujian Road, Shanghai, 200127, China
No. 22, Zhongguancun South Avenue, Haidian, 100081, China
100 Kexue Avenue, Zhengzhou, 450001, China
No. 154, Anshan Road, Xiaobailou, 300052, China
Hunan Provincial Key Laboratory Of Mathematical Modeling And Analysis In Engineering, Changsha, 410114, China
193 Tunxi Road, Hefei, 230009, China
Zheda Road 38, Hangzhou, 310027, China
No.1 Panfu Road, Guangzhou, 510180, China
No. 6, Haierxiang North Road, Nantong, 226001, China
Department Of Otorhinolaryngology Head And Neck Surgery, Beijing, China
1Department Of Endocrinology, No. 6 North Hai‑er‑xiang Road, Nantong, 226001, China
Juqian Street, Changzhou, 213003, China
1095 Jiefang Avenue, Wuhan, 430030, China
Yuquan Road, Yuquan, 100049, China
Suzhou Industrial Park, Suzhou, 215123, China
1630 Dongfang Road, Dongfang, 200127, China
188 Shizi Street, Suzhou, 215006, China
1 Panfu Road, Guangzhou, 510180, China
NO 256, Youyi West Road, Xi'an, 710068, China
Anshan Road, Tianjin, 300052, China
#154 Anshan Road, Tianjin, 300052, China
No. 17 Luyang Road, Hefei, 230011, China
No. 74 Linjiang Road, Linjiang, 400010, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma
A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Device, Drug
Study Drugs: FF/VI, FF/UMEC/VI
Study Phase: Phase 3
COPD Disease Burden, Patient Characteristics, Maintenance Treatment Patterns and Factors Influencing Treatment Decisions in China Tier 2 and Tier 3 Hospitals
COPD Disease Burden, Patient Characteristics, Maintenance Treatment Patterns and Factors Influencing Treatment Decisions in China Tier 2 and Tier 3 Hospitals
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Other
A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation
A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Mepolizumab, Salbutamol
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
To Investigate the PRevention of OM-85 on Bronchiectasis Exacerbation (iPROBE): a Multicenter, Randomised, Double-dummy, Placebo-controlled Clinical Trial in Chinese Patients
To Investigate the PRevention of OM-85 on Bronchiectasis Exacerbation (iPROBE): a Multicenter, Randomised, Double-dummy, Placebo-controlled Clinical Trial in Chinese Patients
Enrollment Status: Completed
Publish Date: April 21, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

1316 Total Publications

Regulating hydroxyl species over Pd-based nanowires towards enhanced direct electrooxidation of ethylene to ethylene glycol.
Regulating hydroxyl species over Pd-based nanowires towards enhanced direct electrooxidation of ethylene to ethylene glycol.
Journal: Dalton transactions (Cambridge, England : 2003)
Published: September 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Cao's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 166 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile